Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)

NSE:SUNPHARMA Stock Forecast

Stock Price Forecast

According to 34 analysts polled by S&P Global, NSE:SUNPHARMA stock has a consensus rating of "Buy" and an average price target of ₹2,040. The average 1-year stock price forecast is 13.97% higher than the current stock price, while the lowest is ₹1,650 (-7.82%) and the highest is ₹2,366 (+32.19%).

Price Target: ₹2,040 (+13.97%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	₹1,650	₹2,040	₹2,050	₹2,366
Change	-7.82%	+13.97%	+14.53%	+32.19%

* Price targets were last updated on Feb 17, 2026.

Analyst Ratings

The average analyst rating for NSE:SUNPHARMA stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	22	22	24	23	22	22
Buy	11	11	9	9	7	8
Hold	1	1	0	0	0	0
Sell	2	2	2	2	2	2
Strong Sell	2	2	2	2	1	1
Total	38	38	37	36	32	33

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Unknown Analyst Geojit Research No rating	Geojit Research	Buy Maintains ₹1,899	Buy	Maintains	₹1,899	+6.10%	Feb 17, 2026
Unknown Analyst ICICI Securities No rating	ICICI Securities	Buy Maintains ₹1,910	Buy	Maintains	₹1,910	+6.71%	Feb 1, 2026
Unknown Analyst Motilal Oswal No rating	Motilal Oswal	Buy Maintains ₹1,940	Buy	Maintains	₹1,940	+8.39%	Jan 31, 2026

Financial Forecast

Revenue This Year

653.94B

Increased by 11.86%

from 584.62B

Revenue Next Year

728.57B

Increased by 11.41%

from 653.94B

EPS This Year

54.92

Increased by 14.89%

from 47.80

EPS Next Year

64.67

Increased by 17.76%

from 54.92

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	386.54B	438.86B	484.97B	525.78B	584.62B	653.94B
Revenue Growth	15.39%	13.53%	10.51%	8.42%	11.19%	11.86%
Gross Profit	277.78B	325.67B	370.55B	410.20B	469.18B	521.11B
Gross Margin	71.86%	74.21%	76.41%	78.02%	80.25%	79.69%
Operating Income	81.56B	93.06B	105.20B	126.05B	135.53B	156.93B
Net Income	32.73B	84.74B	95.76B	109.29B	114.79B	132.87B
EPS	13.60	35.30	39.90	45.55	47.80	54.92
EPS Growth	12.40%	159.56%	13.03%	14.16%	4.94%	14.89%
Forward PE	28.54	28.97	42.36	35.80	34.42	32.59
Dividend / Share	10.00	11.50	13.50	16.00	16.00	15.63
Dividend Growth	-	15.00%	17.39%	18.52%	-	-2.28%
Free Cash Flow	75.69B	7.91B	75.83B	82.40B	49.32B	56.03B
No. Analysts	-	-	-	-	-	34

Financial currency is INR.

Revenue Forecast

Revenue	2027	2028	2029
High	705.1B
Avg	653.9B
Low	635.0B

Revenue Growth

Revenue Growth	2027	2028	2029
High	20.6%
Avg	11.9%
Low	8.6%

EPS Forecast

EPS	2027	2028	2029
High	62.10
Avg	54.92
Low	40.40

EPS Growth

EPS Growth	2027	2028	2029
High	29.9%
Avg	14.9%
Low	-15.5%

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.